Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Mirati Therapeutics, Inc. (MRTX : NSDQ)
 
 • Company Description   
Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.

Number of Employees: 418

 
 • Price / Volume Information   
Yesterday's Closing Price: $63.35 Daily Weekly Monthly
20 Day Moving Average: 881,369 shares
Shares Outstanding: 55.53 (millions)
Market Capitalization: $3,517.63 (millions)
Beta: 1.61
52 Week High: $195.99
52 Week Low: $51.16
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.08% -0.45%
12 Week -28.45% -19.59%
Year To Date -56.81% -47.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3545 CRAY COURT
-
SAN DIEGO,CA 92121
USA
ph: 858-332-3410
fax: -
ir@mirati.com http://www.mirati.com
 
 • General Corporate Information   
Officers
David D. Meek - Chief Executive Officer and President
Faheem Hasnain - Chairman
Vickie S. Reed - Senior Vice President and Chief Accounting Officer
Bruce L.A. Carter - Director
Julie Cherrington - Director

Peer Information
Mirati Therapeutics, Inc. (CORR.)
Mirati Therapeutics, Inc. (RSPI)
Mirati Therapeutics, Inc. (CGXP)
Mirati Therapeutics, Inc. (BGEN)
Mirati Therapeutics, Inc. (GTBP)
Mirati Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60468T105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 55.53
Most Recent Split Date: 7.00 (0.02:1)
Beta: 1.61
Market Capitalization: $3,517.63 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-3.53 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-14.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.82
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -27.34%
vs. Previous Quarter: 8.60%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 137.12%
ROE
03/31/22 - -52.23
12/31/21 - -47.79
09/30/21 - -39.99
ROA
03/31/22 - -45.17
12/31/21 - -41.72
09/30/21 - -35.36
Current Ratio
03/31/22 - 10.87
12/31/21 - 10.50
09/30/21 - 9.60
Quick Ratio
03/31/22 - 10.87
12/31/21 - 10.50
09/30/21 - 9.60
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -867.01
12/31/21 - -802.43
09/30/21 - -653.00
Book Value
03/31/22 - 22.50
12/31/21 - 25.24
09/30/21 - 21.00
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©